| 1 |
Irinotecan FDA Label
|
| 2 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6823).
|
| 3 |
Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
|
| 4 |
Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
|
| 5 |
ClinicalTrials.gov (NCT01009073) A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
|
| 6 |
ClinicalTrials.gov (NCT03416517) Anlotinib and Irinotecan for Ewing Sarcoma
|
| 7 |
ClinicalTrials.gov (NCT00473616) Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
|
| 8 |
ClinicalTrials.gov (NCT00061932) Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
|
| 9 |
ClinicalTrials.gov (NCT00103259) Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
| 10 |
ClinicalTrials.gov (NCT01367275) Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
|
| 11 |
ClinicalTrials.gov (NCT00298675) Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors
|
| 12 |
ClinicalTrials.gov (NCT01304602) A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer
|
| 13 |
ClinicalTrials.gov (NCT00387660) Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
|
| 14 |
ClinicalTrials.gov (NCT01941316) Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
|
| 15 |
ClinicalTrials.gov (NCT00177853) Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer
|
| 16 |
ClinicalTrials.gov (NCT00033657) Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
|
| 17 |
ClinicalTrials.gov (NCT00003900) Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
|
| 18 |
ClinicalTrials.gov (NCT00004235) Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
|
| 19 |
ClinicalTrials.gov (NCT02596503) A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
|
| 20 |
ClinicalTrials.gov (NCT03245450) Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
|
| 21 |
ClinicalTrials.gov (NCT00940316) Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
|
| 22 |
ClinicalTrials.gov (NCT00991952) Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
|
| 23 |
ClinicalTrials.gov (NCT00063960) Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer
|
| 24 |
ClinicalTrials.gov (NCT00193596) Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
|
| 25 |
ClinicalTrials.gov (NCT01896856) Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
|
| 26 |
ClinicalTrials.gov (NCT00022698) Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
|
| 27 |
ClinicalTrials.gov (NCT00003594) Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
|
| 28 |
ClinicalTrials.gov (NCT00031681) 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
|
| 29 |
ClinicalTrials.gov (NCT00827684) Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
|
| 30 |
ClinicalTrials.gov (NCT00027612) Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
| 31 |
ClinicalTrials.gov (NCT00002759) Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
|
| 32 |
ClinicalTrials.gov (NCT00074321) Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
|
| 33 |
ClinicalTrials.gov (NCT02157792) M6620 First in Human Study
|
| 34 |
ClinicalTrials.gov (NCT02801097) RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
|
| 35 |
ClinicalTrials.gov (NCT00671801) Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
|
| 36 |
ClinicalTrials.gov (NCT02611024) Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
| 37 |
ClinicalTrials.gov (NCT04095221) A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
|
| 38 |
ClinicalTrials.gov (NCT05694715) Combination Therapy in Cancers With Mutations in DNA Repair Genes
|
| 39 |
ClinicalTrials.gov (NCT02044120) ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
|
| 40 |
ClinicalTrials.gov (NCT02327169) A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
|
| 41 |
ClinicalTrials.gov (NCT02024607) A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
|
| 42 |
ClinicalTrials.gov (NCT01040312) An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
|
| 43 |
ClinicalTrials.gov (NCT02813135) European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
|
| 44 |
ClinicalTrials.gov (NCT00191984) A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer
|
| 45 |
ClinicalTrials.gov (NCT01347866) Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
|
| 46 |
ClinicalTrials.gov (NCT02283359) Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
|
| 47 |
ClinicalTrials.gov (NCT05177276) Selinexor Combination Ph 1 Study
|
| 48 |
ClinicalTrials.gov (NCT00119236) 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
|
| 49 |
ClinicalTrials.gov (NCT00099125) Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
| 50 |
ClinicalTrials.gov (NCT00311584) Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
|
| 51 |
ClinicalTrials.gov (NCT04525014) RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
|
| 52 |
ClinicalTrials.gov (NCT01141244) Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
|
| 53 |
ClinicalTrials.gov (NCT04067115) SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients
|
| 54 |
ClinicalTrials.gov (NCT04543916) Venetoclax and Irinotecan in Relapsed/Refractory SCLC
|
| 55 |
ClinicalTrials.gov (NCT00006095) Combination Chemotherapy in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
|
| 56 |
ClinicalTrials.gov (NCT03702985) Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
|
| 57 |
ClinicalTrials.gov (NCT03493061) A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM
|
| 58 |
ClinicalTrials.gov (NCT05643677) Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
|
| 59 |
ClinicalTrials.gov (NCT02405585) Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
|
| 60 |
ClinicalTrials.gov (NCT00216086) Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
|
| 61 |
ClinicalTrials.gov (NCT00433550) Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer
|
| 62 |
ClinicalTrials.gov (NCT01558869) Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma
|
| 63 |
ClinicalTrials.gov (NCT00084617) Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
|
| 64 |
ClinicalTrials.gov (NCT04097444) CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC
|
| 65 |
ClinicalTrials.gov (NCT02376452) Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
|
| 66 |
ClinicalTrials.gov (NCT03641313) Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
|
| 67 |
ClinicalTrials.gov (NCT02096354) A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
| 68 |
ClinicalTrials.gov (NCT03251417) Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
|
| 69 |
ClinicalTrials.gov (NCT03030937) Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA
|
| 70 |
ClinicalTrials.gov (NCT02035137) 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
|
| 71 |
ClinicalTrials.gov (NCT03829462) Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
|
| 72 |
ClinicalTrials.gov (NCT05153239) Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
|
|
|
|
|
|
|
